Xalud Therapeutics Inc.
The University of Colorado Connection
Xalud Therapeutics is a clinical-stage biotechnology company developing a non-viral plasmid DNA (pDNA)-delivered gene therapy platform to restore immune system homeostasis and address chronic inflammation. Its lead candidate, XT-150, expresses a proprietary form of interleukin-10 (IL-10v) and is being developed for musculoskeletal and neurodegenerative conditions with high unmet need.
The company’s foundational science originated in the lab of Linda Watkins (CU Boulder Psychology and Neuroscience). Xalud represents a successful example of how CU Boulder research can progress toward clinical development and ultimately impact patients.
Funding Status and Investment Opportunities
- Industry Applications: Health and Wellness, Biotech, Therapeutics
- Funding Stage: Series B or Beyond
- Contact for Investment Inquiries: hello@xaludthera.com
In the News
- To Health: Xalud Therapeutics is bringing gene therapy to the masses (2023)
- Xalud Therapeutics completes oversubscribed $30M Series C financing (2021)
- New gene therapy eases chronic pain in dogs; human trials underway (2018)
- Patented pain treatment shows promise in dogs, hope for humans (2014)
- CU-Boulder, vet hospital team up for clinical study to treat canine pain (2012)
Venture Partners Programs
- Intellectual Property Management (2009, pre-dating Venture Partners Xalud began working with CU's then Technology Transfer Office)
Technology Development Funding
U.S. National Institutes of Health (NIH)
This page was last updated on July 28, 2025. Please email vpnews@colorado.edu for corrections or updates.
The Insider Investor E-Newsletter
Media Inquiries
For marketing inquiries and news tips, contact Daniel Leonard, senior marketing and communications specialist for Venture Partners at CU Boulder.
For media inquiries, please visit colorado.edu/news/formedia.